Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Physics 4, 28. 10.1186/s40658-017-0193-4 file

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Katarina Sjögreen Gleisner1*, Emiliano Spezi2, Pavel Solny3, Pablo Minguez Gabina4, Francesco Ciccone5, Caroline Stokke6, Carlo Chiesa7, Maria Paphiti8, Boudewijn Brans9, Mattias Sandström10, Jill Tipping11, Mark Konijnenberg12 and Glenn Flux13

Abstract

Background: Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries.

Methods: An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription.

Results: Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were 131I-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders. The percentage of responders that reported that dosimetry was included on an always/majority basis differed between the therapies and showed a median value of 36%. The highest percentages were obtained for 177Lu-PSMA therapy (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols. The highest number of absorbed-dose based prescriptions were reported for 90Y microsphere treatments in the liver (64% and 96% of responses for resin and glass, respectively), 131I-Nal treatment of benign thyroid diseases (38% of responses), and for 131I-mIBG treatment of neuroblastoma (18% of responses).

Conclusions: There is a wide variation in MRT practice across Europe and for different therapies, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments.

Keywords: Molecular radiotherapy, Radionuclide therapy, Radiopharmaceutical therapy, European survey, Dosimetry
**Background**

Molecular radiotherapy (MRT) refers to the use of internally distributed, unsealed radioactive substances for the treatment of benign and malignant diseases. These radioactive substances, namely radiopharmaceuticals, represent the combination of an unstable radionuclide with an active or pharmacologically inert molecule. The energy released by the radionuclide at decay determines or boosts the therapeutic effect of the vector molecule. Initial reports of MRT in humans date back to the period between 1938 and 1939, when several patients suffering from chronic myeloid and lymphoid leukemia were treated with repeated oral administrations of $^{32}$P sodium phosphate, which accumulates in blood cells [1].

Therapeutic radiopharmaceuticals are often administered intravenously, although oral, intra-cavity, and intra-arterial administrations are also employed. They are designed to accumulate in a target tissue and, if administered systemically, are able to simultaneously treat disseminated disease which represents a clear advantage over other more localized radiotherapy modalities. Suitable radionuclides for therapy emit particle radiation, such as electrons from $\beta^-$-decay or alpha particles, and have a longer physical half-life compared to radionuclides used for diagnostic purposes. In addition, most therapeutic radionuclides have associated nuclear emissions (positrons or gamma rays) or yield bremsstrahlung during the slowing-down of electrons. The resulting photon radiation can be detected by external probes or imaged by scintillation cameras, either in planar mode or employing single-photon (SPECT) or positron emission (PET) tomography, offering the unique possibility of live imaging and measurement of the distribution of the therapeutic agent in vivo. Based on the results of such measurements, the distribution of activity and absorbed dose can be individually determined for the relevant organs and target tissues.

For radiotherapy modalities such as external beam radiotherapy or brachytherapy, it would not be acceptable to treat patients without an accurate therapy planning, including determination of the absorbed doses delivered to target tissues and to organs at risk. For MRT, however, personalized dosimetry-based treatments have been the slowest to develop among the existing radiotherapy modalities. A forthcoming Council Directive (2013/59/Euratom) [2] mandates the use of dosimetry-based treatment planning and verification of the absorbed doses delivered. In Chapter VII, Medical Exposures, Article 56, Optimisation, it is stated that:

> For all medical exposure of patients for radiotherapeutic purposes, exposures of target volumes shall be individually planned and their delivery appropriately verified taking into account that doses to non-target volumes and tissues shall be as low as reasonably achievable and consistent with the intended radiotherapeutic purpose of the exposure.

According to the same Directive (Chapter II, Definitions, Article 4, Definitions):

> “radiotherapeutic” means pertaining to radiotherapy, including nuclear medicine for therapeutic purposes.
This directive is to be implemented in national legislations by 6 February 2018.

The EANM Internal Dosimetry Task Force (IDTF) was formed to address aspects of the 2013/59/ Euratom Directive specifically concerned with dosimetry for MRT. This task force has representation from Belgium, Czech Republic, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden, Switzerland, Turkey, and the UK. To the best of the knowledge of this group, the current practice of MRT and implementation of dosimetry in clinical routine and research is poorly investigated. In 1999, results from a questionnaire distributed among EANM representatives were reported [3], which mainly addressed the practice of MRT from a clinical and medical point of view. A wide variation in therapy practice across European centers was revealed, and the authors concluded that there was a need of more uniform guidelines and legislations. Since then, the role of MRT has expanded, as more radiopharmaceuticals and treatments have been introduced. Hence, the motivation has grown to undertake a survey with the aim of defining a clear picture of the practice and variation in MRT across Europe and the current readiness of compliance with the 2013/59/Euratom Directive.

Methods
The survey was developed by the IDTF and focused on treatments given during the year 2015. It was written in English and implemented in a web-based questionnaire. The survey was structured so that it could be completed from start to end or by navigating to particular therapies by choice. It could also be saved and continued at a later time. An introductory page explained the survey aim, gave an overview of the included therapies, and contained an option to accept or decline that results, if anonymized but traceable to the country, would be made public.

Survey on therapies
The electronic questionnaire was constructed as one page per therapy. There were 18 explicitly considered therapies, as listed in Table 1. In addition to these, there were three pages for “Therapy using alpha emitting radionuclides other than $^{223}\text{Ra}$” and three pages for “Therapy using other radiopharmaceutical.”

Each therapy page consisted of three sections. The first section was common for all therapies and addressed (a) the number of patients and treatments performed in 2015, (b) the medical specialty owning the license to administer treatment, (c) whether a medical physicist was involved in each treatment, (d) if the absorbed dose was individually planned, (e) whether post-therapy imaging was conducted, and (f) if post-therapy dosimetry was performed.

The second section concerned the basis of prescription for the particular therapy with 12 possible options (Table 2). The typical options included were 1–6 and 12, and multiple replies could be given. Alternative 7 was included for treatments using $^{32}\text{P}$ sodium-phosphate or $^{90}\text{Y}$-ibritumomab-tiuxetan, whereas alternatives 8–11 were included for $^{90}\text{Y}$ microsphere therapies. The subsequent questions specified the relevant responses, asking for the amount and unit of the prescription.

The third section concerned other therapy-specific questions. These included (a) whether or not the therapy is generally repeated, (b) the typical repetition frequency, and (c) for which reason a planned sequence of therapies would be discontinued. The response types in this section were given as drop-down lists, multiple choice questions, or free-text comments.
The final page concerned more general questions, on (a) the satisfaction of the current implementation of patient-specific dosimetry in the center, (b) which factors limit its implementation, and (c) whether any research was conducted. The time required for responding was largely determined by the number of therapies that a particular center was providing and whether data on patient statistics over 2015 had been compiled prior to responding. The survey was launched June 6, 2016, by the EANM Office and via the official route by the EANM National delegates in 40 different countries. In July 2016, kind reminders were sent to the delegates and the survey was also distributed via other channels such as national networks, societies of medical physicists and nuclear medicine practitioners, as well as personal contacts. The survey was closed on September 16, 2016.

### Data analysis

All entries in the web-database were exported to a file and curated manually. This process included merging records and removing duplicate entries and inconsistent data. The spreadsheet was then imported, processed, and analyzed in the Interactive Data Language (IDL, Harris Geospatial Solutions, Broomfield, CO).

### Results

The total number of responders was 208, geographically distributed over 26 countries in Europe, as shown in Fig. 1.

---

**Table 1** Therapy types included in the survey, each on a separate page. Therapies A–R were explicitly asked for, while S–U and V–X were included as complement.

| Annotation | Therapy type |
|------------|--------------|
| A          | $^{131}$I-NaI for benign thyroid diseases |
| B          | $^{131}$I-NaI for thyroid remnant ablation of adults |
| C          | $^{131}$I-NaI for thyroid remnant ablation of children and young adults |
| D          | $^{131}$I-NaI for thyroid cancer therapy for adults |
| E          | $^{131}$I-NaI for thyroid cancer therapy for children and young adults |
| F          | $^{131}$I-mIBG for neuroblastoma |
| G          | $^{131}$I-mIBG for adult neuroendocrine tumors |
| H          | $^{177}$Lu-somatostatin analogues for neuroendocrine tumors |
| I          | $^{90}$Y-somatostatin analogues for neuroendocrine tumors |
| J          | $^{177}$Lu-PSMA therapy of castration resistant prostate cancer |
| K          | $^{90}$Y resin microspheres (SIR-Spheres*) for intra-arterial treatments in the liver |
| L          | $^{90}$Y glass microspheres (TheraSphere*) for intra-arterial treatments in the liver |
| M          | Radiation synovectomy using $^{90}$Y, $^{186}$Re, or $^{169}$Er-colloids |
| N          | $^{153}$Sm-EDTMP (Quadramet*) for bone metastases |
| O          | $^{89}$SrCl$_2$ (Metastron*) for bone metastases |
| P          | $^{223}$RaCl$_2$ (Xofigo*) for bone metastases |
| Q          | $^{32}$P sodium-phosphate (Na$_3^3$P$_4$O$_{12}$) for myeloproliferative disease |
| R          | $^{90}$Y-ibritumomab-tiuxetan (Zevalin*) for B-cell lymphoma |
| S–U        | Therapy using alpha emitting radionuclides other than $^{223}$Ra |
| V–X        | Therapy using other radiopharmaceuticals |
Table 2 Reply alternatives for the question “What basis of prescription do you typically use?”
Therapy types are denoted A–R, as listed in Table 1. Alternatives denoted “All” implies that all therapies (A–R) included this option

| No. | Included in questions | Prescription basis |
|-----|-----------------------|--------------------|
| 1   | All                   | Fixed activity     |
| 2   | All                   | Fixed activity adjusted based on diagnosis, stage, or other clinical factors |
| 3   | A–J, M–R             | Fixed activity calculated per body surface area or patient weight |
| 4   | A–J, N–R             | Individually calculated activity to give a prescribed absorbed dose to whole body |
| 5   | A–J, N–R             | Individually calculated activity to give a prescribed absorbed dose to organ at risk |
| 6   | A–J, M–R             | Individually calculated activity to give a prescribed absorbed dose to target tissue |
| 7   | Q, R                 | Stepwise escalation of activity based on patient response |
| 8   | K, L                 | Body-Surface-Area (BSA) method with reductions |
| 9   | K, L                 | Individually calculated activity based on prescribed absorbed dose to the target volume (lobe or segment) to be treated |
| 10  | K, L                 | Individually calculated activity based on 99mTc MAA SPECT to give a prescribed absorbed dose to non-tumoral liver tissue |
| 11  | K, L                 | Individually calculated activity based on 99mTc MAA SPECT to give a prescribed absorbed dose to tumor |
| 12  | All                  | Other prescription |

Number of patients and number of treatments
Table 3 shows the number of treatments per center in different countries, as well as the total number of treatments. In total, 34,838 patients were reported to be treated in the 208 centers, and as some therapies were administered multiple times, the total number of treatments was slightly higher, and was 42,853. Table 3 also lists the
### Table 3

The number of reported treatments in a country divided by the number of responding centers that administered the particular treatment in that country. On bottom is shown the number of treatments in all countries and all responding centers, as well as the percent of the total number of treatments that represented a particular type of therapy. Therapies are numbered A–R as listed in Table 1.

| Country            | A  | B  | C  | D  | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
|--------------------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Albania            | 25 | 35 | 1.0| 0  | 1.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Austria            | 0  | 0  | 0  | 0  | 0  | 4.0| 0  | 0  | 47 | 0  | 11 | 25 | 2.0| 25 | 0  | 0  | 200| 0  |
| Belgium            | 26 | 24 | 1.8| 14 | 0  | 1.0| 1.5| 1.3| 65 | 0  | 16 | 9.0| 5.0| 2.1| 2.0| 26 | 0  | 0  |
| Bosnia and Herzegovina | 58 | 16 | 0  | 8.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 1.0| 0  |
| Bulgaria           | 38 | 119| 1.0| 112| 2.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Croatia            | 75 | 160| 8.0| 24 | 2.0| 11 | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Cyprus             | 3.0| 100| 1.0| 9.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Czech Republic     | 39 | 239| 9.0| 146| 6.0| 8.0| 19 | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 42 | 16 | 1.5| 5.0| 0  |
| Denmark            | 159| 102| 0  | 111| 0  | 0  | 1.0| 3.0| 57 | 0  | 5.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| France             | 20 | 62 | 0  | 44 | 0  | 0  | 0  | 0  | 20 | 0  | 0  | 4.0| 14 | 20 | 2.0| 1.0| 0  | 0  |
| Germany            | 255| 69 | 4.0| 56 | 5.5| 6.0| 2.5| 111| 38 | 36 | 12 | 46 | 7.0| 42 | 0  | 5.0| 0  | 0  |
| Greece             | 17 | 247| 2.0| 94 | 0  | 0  | 3.0| 4.3| 9.0| 0  | 0  | 0  | 0  | 8.8| 3.0| 0  | 0  | 0  |
| Hungary            | 187| 44 | 0  | 5.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 4.0| 0  | 0  | 0  | 0  |
| Ireland            | 16 | 17 | 0  | 6.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 2.0| 0  | 0  | 5.5|
| Italy              | 96 | 253| 7.9| 82 | 12 | 2.3| 2.5| 160| 333| 0  | 27 | 14 | 27 | 6.2| 31 | 0  | 3.2| 0  |
| Latvia             | 198| 118| 0  | 104| 0  | 1.0| 1.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Netherlands        | 72 | 15 | 2.0| 9.2| 0  | 6.0| 4.0| 296| 0  | 0  | 28 | 50 | 3.3| 7.8| 2.7| 22 | 2.3| 0  |
| Norway             | 47 | 27 | 0  | 67 | 0  | 2.0| 2.0| 0  | 0  | 0  | 0  | 0  | 0  | 3.0| 2.5| 0  | 58 | 0  |
| Portugal           | 36 | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Serbia             | 95 | 124| 4.0| 53 | 1.5| 2.0| 6.0| 32 | 36 | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Slovakia           | 31 | 458| 4.0| 288| 4.0| 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Spain              | 181| 114| 3.5| 65 | 1.0| 2.0| 2.5| 3.0| 0  | 0  | 6.0| 6.0| 22 | 1.3| 0  | 26 | 2.0| 1.0|
Table 3 The number of reported treatments in a country divided by the number of responding centers that administered the particular treatment in that country. On bottom is shown the number of treatments in all countries and all responding centers, as well as the percent of the total number of treatments that represented a particular type of therapy. Therapies are numbered A–R as listed in Table 1 (Continued)

| Country      | A  | B  | C  | D  | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
|--------------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Sweden       | 92 | 46 | 7.0| 15 | 1.5| 1.5| 2.5| 168| 0  | 0  | 14 | 9.0| 0  | 2.7| 1.0| 56 | 8.7| 0  |
| Switzerland  | 37 | 117| 1.5| 33 | 1.0| 0  | 0  | 11 | 0  | 0  | 109| 15 | 8.0| 3.5| 0  | 51 | 0  | 1.0|
| Turkey       | 20 | 50 | 0  | 16 | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 5.0| 0  | 0  | 0  | 0  | 0  | 0  |
| United Kingdom| 86 | 41 | 2.8| 15 | 4.7| 7.0| 3.9| 29 | 20 | 0  | 20 | 5.7| 8.0| 4.0| 2.0| 122| 5.0| 1.0|

Number of treatments in all countries and all responding centers

|                          | 14,426| 11,096| 185   | 4706  | 159  | 113  | 102   | 2417  | 1926  | 363  | 1188  | 394  | 958  | 253  | 42   | 4343  | 138   | 44   |

Percent of total number of treatments

|                          | 34    | 26    | 0.43  | 11    | 0.37 | 0.26 | 0.24  | 5.6   | 0.85  | 2.8  | 0.92  | 2.2  | 0.59 | 0.10 | 10    | 0.32  | 0.10 |
percentage of treatments that represented the different procedures. Therapies involving $^{131}$I-NaI (A–E) represented 71% of the total number of treatments given and 84% of the patients treated in total (data not shown). Of the total number of treatments, 11% were delivered using $^{177}$Lu/$^{90}$Y-somatostatin analogues (peptide-receptor radionuclide therapy, PRRT) (H–I) or $^{177}$Lu-PSMA (J), 10% using $^{223}$RaCl$_2$ (P), 3.7% with $^{90}$Y microspheres (K, L) and 2.2% with radiation synovectomy (M). As seen in Table 3, the therapies in most wide-spread use were those involving $^{131}$I-NaI, in particular for treatment of benign thyroid diseases and thyroid ablation of adults. Certain therapies such as $^{177}$Lu-PSMA (J), $^{90}$Y PRRT (I), $^{32}$P sodium-phosphate (Q), and $^{90}$Y-ibritumomab-tiuxetan (R) were administered only in a few countries.

License to administer treatment

For the question “Which medical specialty owns the license to administer treatment?”, several, non-exclusive replies could be chosen among the alternatives Nuclear Medicine, Medical Oncology, Radiation Oncology, Endocrinology, Interventional Radiology, or Other. Results showed a pronounced weighting towards Nuclear Medicine, for which the average frequency for all treatments was 83%. The average frequencies for the other alternatives were for Medical Oncology (8.5%), Radiation Oncology (6.0%), Endocrinology (1.2%), and Interventional Radiology (1.0%). No center replied Other. The replies were similar for most treatments, exceptions being $^{90}$Y microspheres for which Interventional Radiology was higher at 12% and 6% for resin and glass, respectively, and $^{32}$P sodium-phosphate where the respective frequencies were for Nuclear Medicine (59%), Medical Oncology (22%), and Radiation Oncology (19%). Seventeen countries responded 100% Nuclear Medicine, while the percentage of Nuclear Medicine for the remaining countries were Belgium (96%), Bulgaria (42%), Denmark (92%), Ireland (58%), Italy (94%), Norway (84%), Sweden (30%), Turkey (14%), and UK (37%), as calculated over all therapies.

Imaging, dosimetry, and involvement of medical physicist

For these set of questions, one exclusive reply consisting of Always, Majority, Minority, or Never could be given. The numbers were expressed as frequencies for each therapy, calculated as the number of times a particular response was given divided by the total number of responses for that therapy. Analysis was also made by combining the data into two categories, namely Always/Majority versus Minority/Never, by counting the centers that gave one of the two replies and dividing by the total number of responses for that therapy.

Figure 2a shows the responses on the question “Is a medical physicist involved in each treatment?”. The mean frequencies for all treatments together were for Always (63.9%), Majority (3.7%), Minority (9.7%), and Never (22.7%). When combining the data in two categories, the frequencies were thus 67.6% and 32.4%, for Always/Majority and Minority/Never, respectively. The median of the Always/Majority frequencies was 66% (min 45%, max 88%). The Always/Majority frequency was 50% or higher for all therapies except radiation synovectomy (45%) and $^{90}$Y-ibritumomab-tiuxetan (48%). Treatments for which the Always/Majority frequency was higher than 75% were $^{177}$Lu-PSMA (88%), $^{90}$Y PRRT (83%), $^{32}$P sodium-phosphate (83%), $^{131}$I-mIBG for neuroblastoma (82%), $^{177}$Lu PRRT (79%), $^{131}$I-mIBG for adult neuroendocrine tumors (77%), and $^{90}$Y microspheres of resin (84%) and glass (78%). The highest frequencies were notably
obtained for therapies with a limited geographical spread (\(^{177}\)Lu-PSMA: 2 countries; \(^{90}\)Y PPRT: 6 countries; and \(^{32}\)P sodium-phosphate: 4 countries).

Figure 2b shows the responses to the question “Is the absorbed dose individually planned for each patient?”. The mean frequencies for all treatments together were for Always (33.1%), Majority (3.5%), Minority (8.4%), and Never (55.1%). For the two categories Always/Majority and Minority/Never, the frequencies were thus 36.5% versus 63.5%. The median of the Always/Majority frequencies was 33% (min 11%, max 84%).
The highest frequencies were obtained for $^{90}$Y microspheres, for which 82% (resin) and 84% (glass) of the centers responded Always/Majority, and $^{131}$I-Nal for benign thyroid diseases, where this frequency was 54%.

Figure 2c shows the response frequencies to the question “Is post-therapy imaging performed?”. The mean frequencies for all treatments together were for Always (67.7%), Majority (1.6%), Minority (3.7%), and Never (27.0%). For the two categories Always/Majority and Minority/Never, the respective frequencies were thus 69.3% and 30.7%. The median of the Always/Majority frequencies was 94% (min 0%, max 100%). A group of therapies had more than 50% of the centers respond Minority/Never ($^{131}$I-Nal for benign thyroid diseases, radiation synovectomy, $^{89}$SrCl$_2$, $^{223}$RaCl$_2$, $^{32}$P sodium-phosphate, and $^{90}$Y-ibritumomab-tiuxetan). $^{153}$Sm-EDTMP for bone metastases was close to 50%, whereas for the other therapies post-therapy imaging was being conducted on an Always/Majority basis.

Figure 2d shows the response frequencies to the question “Is post-therapy dosimetry performed?” The mean frequencies for all treatments together were for Always (22.0%), Majority (4.4%), Minority (12.0%), and Never (61.6%). For the two categories Always/Majority and Minority/Never, the respective frequencies were thus 26.4% and 73.6%. The median of the Always/Majority frequencies was 23% (min 0%, max 100%). For two therapies more than 50% of the centers responded Always/Majority, $^{177}$Lu-PSMA (100%) and $^{131}$I-mIBG for neuroblastoma (59%). For PRRT using $^{90}$Y or $^{177}$Lu, as well as $^{131}$I-mIBG for adult neuroendocrine tumors, approximately 40% of the centers responded Always/Majority. For the other therapies, the responses on post-therapy dosimetry were mainly Minority/Never.

To summarize, the highest frequencies of any dosimetry, i.e., either as part of treatment planning or post-therapy and on an Always/Majority basis (Fig. 2b, d), were for $^{177}$Lu-PSMA (100%) and $^{131}$I-mIBG for neuroblastoma (59%). For $^{90}$Y microspheres of glass, the percentage of responders that reported that dosimetry was included on an Always/Majority basis was obtained to a median of 36%.

### Activity prescription

For this set of questions, several, non-exclusive replies could be given, where the alternatives for the different therapies are listed in Table 2. The frequencies were calculated as the occurrence of a particular reply in relation to the total number of replies. Table 4 summarizes the most typically stated prescribed amounts, where for many therapies, a high diversity was obtained among the different prescription alternatives. Occasional outliers, likely caused by typographic errors, were disregarded for this summary.

For therapies involving $^{131}$I-Nal (Fig. 3a, A–E in Table 4), the majority of the responders stated that they use different kinds of fixed-activity schemas, mainly adjusted based on the diagnosis, stage, or other clinical factors. For treatments (B–E), responses 1–3 were given on average for 84% of the replies, while for $^{131}$I-Nal for benign thyroid diseases (A) these responses were given in 54% of the replies, and 71 out of the 188 different responses (38%) stated that the activity was individually calculated to give a prescribed absorbed dose to target tissue.

Likewise, for therapies shown in Fig. 3b (F–J in Table 4) responses 1–3 were most frequent, thus stating that fixed activities were being used, possibly adjusted based on the diagnosis, stage or other clinical factors, or patient weight. For $^{131}$I-mIBG treatment
of neuroblastoma (F), 8 out of 44 responses (18%) stated prescriptions based on the whole-body absorbed dose, with a limit of either 2 or 4 Gy for two subsequent administrations. Prescriptions based on the absorbed dose to organ at risk were reported for 131I-mIBG treatment of adult neuroendocrine tumors in 5/39 of responses (13%), for 177Lu PRRT in 3/38 (8%), and for 90Y PRRT in 2/22 (9%).

For therapies shown in Fig. 3c, including radiation synovectomy, the bone seekers 153Sm-EDTMP, 89SrCl₂, and 223RaCl₂, 32P sodium-phosphate, and 90Y-ibritumomab-tuxetan, prescriptions listed as alternatives responses 1, 2, 3, 7 in Table 2, represented 96% of the replies, calculated as an average of the therapies. Prescriptions for these therapies were thus approximately only based on fixed-activity schemas, with adjustments made.

### Table 4

The most commonly stated prescribed amounts for the different therapies. Therapy notations follow Table 1, whereas prescription alternatives 1–6 refer to Table 2. The prescribed amounts are given either as median, 10th and 90th percentiles, or as median, minimum, and maximum, depending on the replies obtained. The percentiles are used to better accommodate some occasional outlier values.

| Therapy Specification | Prescription alternative according to Table 2 | Median | 10th | 90th | Median | 10th | 90th |
|------------------------|-----------------------------------------------|--------|------|------|--------|------|------|
| A Toxic or nontoxic multinodular goiter | 550 370 740 | 150 120 300 | Gy to target |
| Autonomous nodules | 500 370 770 | 300 200 400 | Gy to target |
| Graves’ disease | 400 222 600 | 200 100 300 | Gy to target |
| B Lowest prescribed amount | 1110 1100 3490 | 1111 6920 | |
| Highest prescribed amount | 4440 3540 7400 | 5500 10,000 | |
| C Lowest prescribed amount | 1110 1000 3700 | 1554 6290 | |
| Highest prescribed amount | 3700 1100 5500 | 3700 7360 | |
| D Lowest prescribed amount | 4000 1111 6920 | 1111 220 | |
| Highest prescribed amount | 7400 5500 10,000 | 3700 7360 | |
| E Lowest prescribed amount | 3700 1100 5500 | 3700 7360 | |
| Highest prescribed amount | 5525 3700 7360 | 3700 7360 | |
| M 90-Y | 185 185 220 | 37 17 39 | |
| 169-Er | 37 17 39 | 77 73 161 | |
| 186-Re | 37 17 39 | 77 73 161 | |
| N 2545 | – – 37 MBq/kg | |
| O 150 | 148 185 | |
| P – | – 0.05–0.055 MBq/kg | |
| Q 185 | – – 3.7–3.9 MBq/kg or 74–111 MBq/m2 | |
| R – | – – 11–15 MBq/kg (median 14.8 MBq/kg) | |
| F 7400 | 2700 9250 | 444 MBq/kg, or 2 or 4 Gy to whole body | |
| G 7400 | 3700 14,800 | 444 MBq/kg, or 2 to whole body | |
| H 7400 | 4000 9175 | 23 or 29 Gy to kidneys | |
| I 2600 | 1480 5550 | 1850–2500 MBq/m², or 23 Gy to kidneys | |
| J 6000 | 3500 7400 | 23 Gy to kidneys | |
For $^{90}$Y-microsphere treatments (K, L), shown in Fig. 3d, the replies differed from above. In this case, the most common responses were prescriptions based on the absorbed dose, either to the target tissue (lobe or segment), or to non-tumor liver tissue or tumor based on $^{99}$mTc-MAA SPECT (Table 2, alternatives 9–11). For resin microspheres, the frequencies were 14/85 (15%) for alternative 9 in Table 2, 21/85 (25%) for alternative 10, and 19/85 (22%) for alternative 11. For glass microspheres, the corresponding frequencies were 23/48 (48%) for alternative 9, 13/48 (27%) for alternative 10, and 10/48 (21%) for alternative 11. Thus, absorbed-dose based prescriptions were reported in 64% and 96% of responses for resin and glass, respectively. There was a difference between resin and glass microspheres in that the body-surface area method was stated in 28/85 (33%) of the responses for resin, whereas the corresponding number for glass microspheres was 2/48 (4%).

User satisfaction

For the question “Are you satisfied with the current implementation of patient-specific dosimetry in your centre?”, 45% of the responders answered Yes and 55% answered No. For the question “Which factors limit the implementation of patient-specific dosimetry in your centre?”, the reply alternatives were non-exclusive. The listed alternatives and percentage responses were “Shortage of knowledge and know-how” (12%), “Shortage of medical physicists working in nuclear medicine” (20%), “Shortage of other staff” (13%), “Limited access to scanner or other equipment needed” (17%), “Limited access to dedicated software” (16%), “No legislative requirement to perform dosimetry” (12%), and “Other” (10%).
Discussion
To the best of our knowledge, this is the first extensive survey focused on the implementation of MRT and dosimetry. As for surveys in general, results can only be considered as a sample of an underlying true population. The extent to which the results are representative of general practice is dependent on the number of responders, their geographic spread, how well the questions were understood, and whether they could be responded to in a reasonable amount of time. Another factor that may influence the representativeness of our results is that the survey was answered on a voluntary basis and there is the possible risk that centers involved in dosimetry could be more likely to respond. Moreover, the professional role of the individual responder, e.g., physician, medical physicist, or technologist, was not asked for. For this survey, 208 responses were obtained, which we consider to be good. However, results from this survey should be regarded as a starting point with results that provide a snapshot of the current situation.

Total number of centers administering MRT in Europe
To our knowledge, there is no current record of the number of MRTs performed in Europe. The International Atomic Energy Agency (IAEA) keeps a database on nuclear medicine practice around the world, in which the total number of therapies in different countries is included. However, this database, intended mainly for developing countries, is compiled on a voluntary basis. As a result, the data are by no means complete and for many European countries are below the number of therapies reported in this survey. Furthermore, information on the different kinds of MRTs is not available in the IAEA database. In 1999, the EANM Radionuclide Therapy Task Group reported on results from two questionnaires, distributed in 1993 to national advisors or members of the task group, with data acquired from 16 and 20 European countries [3]. The number of centers administering MRT in different countries was reported, identifying a total of 630 centers. In addition to that survey [3], a few national surveys have been identified [4, 5], as well as one reviewing nuclear medicine in the Middle East [6].

To address the shortage of information and put results of the current survey into perspective, the ITDF made an effort, after the survey was closed, to compile data of the number of centers that administer MRT in the countries from where responses were obtained (Table 5). The information sources identified were the EANM national delegates, national authorities or societies, published national data, and in some cases, personal communication or data retrieved from [3]. For the 25 countries where data could be obtained, a total of 925 centers were recorded. The 208 responders in the current survey were thus estimated to represent approximately 20% of the existing centers. For the future, a European database of centers performing MRT would need to be established in order to achieve complete overview of the situation. Similar initiatives have been undertaken in external beam radiotherapy as part of the ESTRO Health Economics in Radiation Oncology project [7].

Survey construction and dissemination
For this survey, there were evident challenges in reaching responders, resulting in an irregular response rate between countries (Fig. 1 and Table 5). Following the initial launch via the official route of dissemination, the response rate was rather modest, and
we partly relied on national networks through which the survey could be forwarded. The construction of the survey lasted almost 1 year and built upon discussions in the ITDF, taking the different national perspectives into account, and the fact that different radionuclide therapies have different treatment aims, procedures for administration, level of patient hospitalization, profiles of treatment-related risks, and ease of implementation of dosimetry. During these discussions, a number of potential problems were identified, especially concerning the terminology that is not well established. For instance, the modality itself runs under various names such as “nuclear medicine therapy,” “radiopharmaceutical therapy,” and “(targeted) radionuclide therapy,” in addition to “molecular radiotherapy,” as used herein. Another ambiguous term is the word “treatment,” which for radionuclide therapies involving planned repeated administrations may refer to one administration or a series of administrations. Here, terms such as “fraction” or “treatment

Table 5 Number of centers that administer molecular radiotherapy in the countries from where responses were obtained. Numbers have been acquired from a variety of sources, as indicated, and are valid for 2015–2016 except where explicitly stated otherwise

| Country                     | Number of centers | Source of information                                                                 |
|-----------------------------|-------------------|---------------------------------------------------------------------------------------|
| Albania                     | No information    |                                                                                       |
| Austria                     | 7                 | Only number of inpatient facilities, personal communication                            |
| Belgium                     | 143               | Number of licensed sites. Registry of the Belgian Federal Agency for Nuclear Control    |
| Bosnia and Herzegovina      | 3                 | EANM National Delegate                                                                 |
| Bulgaria                    | 11                | EANM National Delegate                                                                 |
| Croatia                     | 6                 | EANM National Delegate                                                                 |
| Cyprus                      | 5                 | Ministry of Health (public hospitals) and personal communication (private hospitals)  |
| Czech Republic              | 47                | Institute of Health Information and Statistics of the Czech Republic (online)          |
| Denmark                     | 14                | EANM National Delegate                                                                 |
| France                      | 60                | Valid 1999, reference [3]                                                              |
| Germany                     | 114               | Valid 2012, reference [5]                                                              |
| Greece                      | 33                | Greek Atomic Energy Commission                                                        |
| Hungary                     | 13                | EANM National Delegate                                                                 |
| Ireland                     | 14                | EANM National Delegate                                                                 |
| Italy                       | 106               | Valid 2006, White paper of Italian Association of Nuclear Medicine (online)            |
| Latvia                      | 1                 | EANM National Delegate                                                                 |
| Netherlands                 | 66                | Valid 2014, Dutch health research institute (online)                                   |
| Norway                      | 19                | Norwegian Radiation Protection Authority                                               |
| Portugal                    | 32                | Ministry of Health of Portugal                                                        |
| Serbia                      | 7                 | EANM National Delegate                                                                 |
| Slovakia                    | 16                | National Health Information Center (Slovakia)                                         |
| Spain                       | 90                | National Safety Council of Spain                                                      |
| Sweden                      | 24                | Swedish Society of Radionuclide Therapy (online)                                       |
| Switzerland                 | 13                | Only number of inpatient facilities, personal communication                            |
| Turkey                      | 11                | Valid 1999, reference [3]                                                              |
| United Kingdom              | 70                | Estimated, personal communication                                                     |
“cycle” have sometimes been borrowed from other treatment modalities although these may be more or less suited within the context of particular therapies. The need to develop standardized terminology is thus evident. For the question concerning the involvement of a medical physicist, it was recognized that the word “involved” could be clarified further. However, also in the Council Directive (2013/59/Euratom), the word “involved” is being used without clarification, and seeing that one of the aims was to understand the compliance to that Directive, it was decided to maintain this wording. The prescription basis was particularly difficult to summarize in a few questions, in view of the quite different treatment protocols applied in different countries and within countries. To some extent, this can be seen as a result in its own, pointing to the diversity of treatment protocols that are being employed for patients in Europe.

**Results for treatments, the use of dosimetry, and the involvement of medical physicists**

The most commonly performed therapies were clearly $^{131}$I-NaI for benign thyroid diseases and thyroid ablation of adults (Table 3, therapies A and B). These were also the therapies with largest geographical spread. As shown in Fig. 2, 54% of the responses stated that absorbed-dose planning was being undertaken in treatments of benign thyroid diseases in Always/Majority of treatments, while the same number, 54%, responded that a medical physicist was involved (Always/Majority). For $^{131}$I-NaI thyroid ablation of adults, 23% of the responses stated that absorbed-dose planning was undertaken and 21% that post-therapy dosimetry was performed in Always/Majority of treatments, while 55% responded that a medical physicist was involved (Always/Majority). Overall, this suggests that approximately 50% of the responding centers administer these treatments (A and B) without involvement of a medical physicist and without any dosimetry.

The most concerning results are perhaps those presented in Fig. 2a, showing an average frequency of the Minority/Never responses for involvement of a medical physicist of 32%. Without the involvement of a medical physicist, the likelihood that dosimetry can be undertaken is probably low. This may also explain the confusion that was occasionally encountered in the free-text replies, of the generic term dose (for instance in units of MBq), versus the SI-derived quantity absorbed dose (in unit Gy). The survey questions clearly distinguished between activity and absorbed dose and did not use the term “dose” without specification. Thus, the possible confusion between administered activity and absorbed dose was not likely caused by the wording of the survey questions. However, seeing that the general term “dose” is often used in nuclear medicine, misunderstandings may still exist.

Among the therapies not involving $^{131}$I-NaI, $^{223}$RaCl$_2$ therapies for bone metastases accounted for 3.3% of the total patients treated (data not shown). Given that repeated administrations are foreseen in the therapy protocol [8], this corresponded to 10% of the total radionuclide treatments in our survey (Table 3, therapy P). Concerning the geographical spread, 13 of the countries from which responses were obtained gave this treatment. This is a comparably high number in view of the short history of this therapy. Although imaging and dosimetry of $^{223}$RaCl$_2$ presents several challenges [9–11], 38% of centers responded that the absorbed dose was individually planned, 17% that post-therapy imaging was performed, and 4% that post-therapy dosimetry was performed, on an Always/Majority basis. In view of the practical difficulties in performing
absorbed-dose planning for $^{223}$RaCl$_2$ and that 98% of responses on the activity prescription stated different kinds of fixed-activity protocols, these figures appear unlikely and raise the question on the understanding of the concept of individual-based absorbed-dose determination. It is possible that responders did not distinguish between an individually calculated absorbed dose and the absorbed-dose estimation per unit of administered activity available in the package insert.

Other comparably frequent treatments were $^{177}$Lu or $^{90}$Y PRRT (Table 3, therapies H and I). PRRTs are given as repeated administrations, and while the percentages of the treated patients were 3% (H) and 1% (I) (data not shown), the percentages of the given number of treatments were 6% (H) and 5% (I). Concerning the geographical spread, 13 out of the 26 countries were administering either of these treatments. This is a relatively high proportion considering that neither of these therapies is yet approved for clinical use by the European Medicines Agency (EMA). For the responses Always/Majority (Fig. 2), 15% (H) and 33% (I) of centers responded that the absorbed dose was individually planned, 100% (H) and 89% (I) that post-therapy imaging was performed, and 44% (H) and 39% (I) that post-therapy dosimetry was performed. These results appear somewhat more consistent than for $^{223}$RaCl$_2$, since the practical implementation of imaging and post-therapy dosimetry is more straightforward [12, 13], and since without EMA approval, these therapies are probably to a larger extent administered as part of clinical trials.

The most frequent application of any dosimetry, i.e., responses in the Always/Majority category either as part of treatment planning or on a post-therapy basis (Fig. 2), was reported for $^{177}$Lu-PSMA (100%), $^{90}$Y microspheres of glass (84%) and resin (82%), $^{131}$I-mIBG for neuroblastoma (59%), and $^{131}$I-NaI for benign thyroid diseases (54%). Possible explanations for these results are that $^{177}$Lu-PSMA is yet not approved for clinical use by the EMA and is thus being evaluated as part of clinical trials in a limited number of centers (2 of the 26 countries). For $^{90}$Y microspheres, the risks for radiation-induced liver disease are of clinical concern, and at the same time, patient-specific dosimetry can be accomplished using only one patient scan [14]. Dosimetry in $^{131}$I-mIBG for neuroblastoma is particularly motivated in view of the pediatric/young patient population. The implementation of dosimetry in $^{131}$I-NaI treatments for benign thyroid disease is compulsory in some countries, which may explain the geographical variability, as further highlighted in Fig. 4.

Free-text comments from the responders

The free-text fields were available on the survey for collecting additional comments from the participants. For instance, some pointed at the lack of information on the tolerance levels of normal organs as an obstacle for clinical implementation of dosimetry, while others argued that prospective, randomized trials for examining the clinical value of dosimetry are needed before implementation. Others pointed at needs for resources and equipment, methodological guidance, and standardization of dosimetry methods. According to the questions on user satisfaction, 45% of the responders were satisfied with the implementation of dosimetry in their center. Interestingly, 12% of responders stated that a limiting factor was that there is no legislative requirement to perform dosimetry.
Summary
In summary, our European survey showed a wide variation in MRT and dosimetry practices. Although MRT has a long history of being prescribed based on different fixed-activity schemas, with successful treatment results obtained in patient groups, this does not mean that the treatment is also optimal for an individual patient. For instance, it has been demonstrated that, for a given administered activity, the absorbed dose to target tissue may vary by more than two orders of magnitude for the same treatment [15]. Correlations between estimated absorbed doses and clinical outcomes have been reported for several types of MRTs [16–22], and some therapeutic prescriptions are already based on dosimetry [23–28]. It is likely that additional therapeutic scenarios would benefit from dosimetry studies. In fact, for some therapies, fixed activities might be too conservative, and patient-based dosimetry might indicate the need for activity escalation in order to achieve the desired dose to the target. On the other hand, in some other cases, dosimetry studies might constrain the activity prescriptions to keep the absorbed doses to non-target organs within safe limits or rule out patients who would not achieve enough absorbed doses to the target, helping to balance risks and benefits on a single patient basis. Furthermore, as pointed out already in 1992 [29], there may be economical incentives for implementation of dosimetry. These authors reported on results of dosimetry-based $^{131}$I-NaI thyroid cancer therapy for adults and found that the savings made on a lower rate of hospitalization well balanced the extra costs for dosimetry. Bearing in mind that we are in an era when personalized treatments are the focus of many kinds of radiotherapy, as well as pharmaceutical therapies,
MRT has an extraordinary advantage in that the pharmaceutical agent and its distribution over time can be monitored and quantified.

Conclusion
There is a wide variation in MRT practice across Europe, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments. In many cases, dosimetry is feasible, and several therapies exist in which dosimetry is being performed on a fairly standardized basis in different centers and countries. However, in respect of the Council Directive (2013/59/Euratom), it appears that there is still a general need to increase the possibilities and benefits of a higher degree of implementation of dosimetry.

Endnotes
1See http://www.eanm.org/about/organisations/national-societies/ for a complete list of national societies.
2http://nucmedicine.iaea.org/

Additional file

Additional file 1: IDTF electronic version of survey results submission and EANM Internal Dosimetry Task Force Survey. (ZIP 801 kb)

Abbreviations
EANM: European association of nuclear medicine; IDTF: Internal dosimetry task force; MRT: Molecular radiotherapy

Acknowledgements
We in the EANM ITDF wish to express our sincere gratitude to all involved professionals who contributed to the survey. We also wish to thank Mrs. Sonja Niederkofler at the EANM Headquarters for all her assistance, and Gian Luca Poli, Medical Physicist, Division of Human Health, IAEA, who kindly provided information on the IAEA database.

Availability of data and materials
The datasets supporting the conclusions of this article (complete survey and responses obtained) are available in the Open Science Framework repository (Additional file 1).

Authors’ contributions
KSG contributed to the implementation of the web-based form, data curation and consistency checks, performed the data analysis, and drafted the manuscript. ES implemented the web-based form and contributed to data curation. PS prepared material for consistency checks. GF initiated the study, maintained communication, and chaired the IDTF. All authors participated in the construction of the survey, data collection, consistency checks, discussion of results, and preparation of the manuscript. All authors read and approved the final manuscript.

Funding
This work was financially supported by the Swedish Research Council (grant no. 621-2014-6187), and the Berta Kamprad Foundation (FBKS 2017-37). The funding bodies had no influence over the conduct or content of the study.

Authors’ information
K. Sjögreen Gleisner, C. Chiesa, and M. Konijnencb are members of the Dosimetry Committee of the EANM. G. Flux is member of the Radiation Protection Committee of the EANM.

Consent for publication
Survey responders agreed to make data, when anonymized but traceable to their country, publicly available.

Competing interests
K. Sjögreen Gleisner, E. Spedi, P. Solny, P. Minguez Gabina, F. Ciccone, C. Stokke, M. Paphiti, B. Brans, M. Sandström, J. Tipping, and M. Konijnencb declare that they have no competing interest. C. Chiesa has received speaker and consultant honoraria, and sponsorship to congresses from BTG Biocompatibles. He has received a consultant honorarium from Medpace CRO. G. Flux received grants for research from BTG Biocompatibles and from Sirtex.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details
1Department of Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden. 2School of Engineering, Cardiff University, Cardiff, UK. 3Department of Nuclear Medicine and Endocrinology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. 4Department of Medical Physics and Radiation Protection, Gurutzeta/Cruces University Hospital, Barakaldo, Spain. 5Nuclear Medicine, Sant Andrea Hospital, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy. 6Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway. 7Nuclear Medicine Division, Foundation IRCCS Istituto Nazionale Tumori, Milan, Italy. 8Department of Medical Physics, Pammakaristos Hospital, Athens, Greece. 9Department of Nuclear Medicine and PET Center, University Hospital, Ghent, Belgium. 10Department of Surgical Sciences, Radiology, Uppsala University Hospital, Uppsala, Sweden. 11The Christie NHS Foundation Trust, Nuclear Medicine, Manchester, UK. 12Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. 13Joint Department of Physics, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.

Received: 17 August 2017 Accepted: 6 November 2017
Published online: 04 December 2017

References
1. Lawrence JH. Nuclear physics and therapy: preliminary report on a new method for the treatment of leukemia and polycythemia. Radiology. 1940;35:51–60. doi:10.1148/35.1.51.
2. Council Directive 2013/59/Euratom. Off J Eur Union. 2014;57 doi: 10.3000/19770677.L_2014.013.eng.
3. Hoefnagel CA, Clarke SE, Fischer M, Chatal JF, Lewington VJ, Nilsson S, et al. Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee. Eur J Nucl Med. 1999;26:277–82.
4. Rojas D, Hooker C, McGowan DR, Guy MJ, Tipping J. Eight years of growth and change in UK molecular radiotherapy with implications for the future: Internal Dosimetry Users Group survey results from 2007 to 2015. Nucl Med Commun. 2017;38:291–4. doi:10.1097/NMN.0000000000000642.
5. Lorenz R, Buck A, Reiners C. Stationäre nuklearmedizinische Therapie 2010 bis 2012 in Deutschland. Nuklearmedizin. 2015;54:61–8. https://doi.org/10.3413/Nukmed-0725-15-02.
6. Paez D, Becic T, Bhonsle U, Jalilian AR, Nunez-Miller R, Osso JA Jr. Current status of nuclear medicine practice in the Middle East. Semin Nucl Med. 2016;46:265–72. doi: 10.1016/j.semnucmed.2016.01.005.
7. Grau C, Defourny N, Malicki J, Dunscombe P, Bonas JM, Coffey M, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:155–64. doi: 10.1016/j.radonc.2014.08.029.
8. Nilsson S, Franzen L, Parker C, Tyrell C, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94. https://doi.org/10.1016/S1470-2045(07)70147-X.
9. Pacilio M, Cassano B, Chiesa C, Giancola S, Ferrari M, Pettinato C, et al. The Italian multicentre dosimetric study for lesion dosimetry in 223Ra therapy of bone metastases: calibration protocol of gamma cameras and patient eligibility criteria. Phys Med. 2016;32:1731–7. doi: 10.1016/j.ejmp.2016.09.013.
10. Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56:1304–9. doi: 10.2967/jnumed.115.157123.
11. Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radonucleide therapy of bone metastases. Nucl Med Commun. 2012;33:726–32. doi: 10.1097/NMC.0b013e328353bb66.
12. Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögren-Gleisner K. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57:151–62. doi: 10.2967/jnumed.115.159012.
13. Van Binnebeek S, Baele K, Vanbilloen B, Tersiveinge C, Kooie M, Mottaghy FM, et al. Individualized dosimetry-based activity reduction of (90)Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2014;41:1141–57. doi: 10.1007/s00259-014-2824-5.
14. Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guarnerio F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210. doi: 10.3389/fonc.2014.00210.
15. Minguez P, Flux G, Genolla M, Delgado A, Rodeno E, Gleisner KS. Whole-remnant and maximum-voxel SPECT/CT dosimetry in 1-131-NaI treatments of differentiated thyroid cancer. Med Phys. 2016;43:10.1118/1.4961742.
16. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(Suppl 1):965–66.
17. Strigari L, Sciotto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with (90)Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377–1385. doi: 10.2967/jnumed.110.075861. (pii). doi: 10.2967/jnumed.110.075861.
18. Paulews S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Klous UK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):925–30.
19. Ilan E, Sandstrom M, Warsberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–82. doi: 10.2967/jnumed.114.148437.
20. Strigari L, Konijnenberg M, Chiesa C, Bardes M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976–88. doi: 10.1007/s00259-014-2824-5.
21. Wiertz R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, et al. Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. J Nucl Med. 2016;57:1027–32. doi: 10.2967/jnumed.115.168799.

22. Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, et al. Tumor-absorbed dose predicts progression-free survival following (131)I-tositumomab radioimmunotherapy. J Nucl Med. 2014;55:1047–53. doi: 10.2967/jnumed.113.1136044.

23. Jonsson H, Mattsson S. Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism. Radiat Prot Dosim. 2004;108:107–14. doi: 10.1093/rpd/nch013.

24. Chesa C, Mira M, Maccuro M, Spreafico C, Romito R, Morosi C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42:1718–38. doi: 10.1007/s00259-015-3068-8.

25. Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:39–41. doi: 10.2967/jnumed.112.107524.

26. Sundlov A, Sjögren-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017; doi: 10.1007/s00259-017-3678-4.

27. Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50:1518–24. doi: 10.2967/ jnumed.109.064469. 50/9/1518 [pii]

28. Verburg FA, Hanscheid H, Bilko J, Hategan MC, Lassmann M, Kreissl MC, et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2010;37:896–903. doi: 10.1007/s00259-009-1303-x.

29. Waxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33:1152–6.